-

Delta-Fly Pharma Inc.: Update on the Interim Analysis Status of Phase III Study of DFP-10917 in the patients with R/R AML

TOKUSHIMA, Japan--(BUSINESS WIRE)--Following the previous information on Jan. 5th. in 2024, we are excited to share our latest development status.

The following is the current status of the interim analysis of a Phase III study of DFP-10917 monotherapy in patients with recurrent or refractory acute myeloid leukemia (R/R AML) at multicenter in the US.

As there are a long term surviving patients in the 150 patients enrolled in this study, we intend to continue to follow up these patients without any data cut-off for the time being to determine the final overall survival (OS) results of the study.

We ask for understanding that under a randomized and controlled study, we are unable to identify at this stage whether these surviving patients are in the DFP-10917 group or the control group (NCT03926624).

We look forward to showing the results when the data is ready to disclose.

Please find out the innovation for the miserable cancer patients by Delta-Fly Pharma Inc. and contact with us.

Contacts

Inquires
Dr. Yasundo Yamasaki
Vice President for Business Development
Delta-Fly Pharma, Inc.
Head office: Tokushima 771-0117, Japan
Phone: +81-3-6231-1278
E-mail: yyamasaki1206@delta-flypharma.co.jp
Home page: https://www.delta-flypharma.co.jp/en/

Industry:

Delta-Fly Pharma, Inc.

Release Versions
EnglishSpanish (Summary)GermanFrenchItalian (Summary)Dutch (Summary)

Contacts

Inquires
Dr. Yasundo Yamasaki
Vice President for Business Development
Delta-Fly Pharma, Inc.
Head office: Tokushima 771-0117, Japan
Phone: +81-3-6231-1278
E-mail: yyamasaki1206@delta-flypharma.co.jp
Home page: https://www.delta-flypharma.co.jp/en/

More News From Delta-Fly Pharma, Inc.

Delta-Fly Pharma, Inc.: Progress of Development Status of the Combination Study of DFP-10917 with Venetoclax

TOKUSHIMA, Japan--(BUSINESS WIRE)--Following to the previous information on Dec. 9th. in 2024, we are excited to share our latest development status. Regarding the Phase I/II clinical trial of DFP-10917 in combination with Venetoclax (VEN) in patients with acute myeloid leukemia (AML) in second-line therapy (NCT06382168), the Data Management Committee (DMC) has approved the tolerability of all six patients in the Phase I (dose finding) portion of the Phase I/II study, and we are moving to the P...

Delta-Fly Pharma Inc.: Update for Development Status of the Combination Study of DFP-10917 with Venetoclax

TOKUSHIMA, Japan--(BUSINESS WIRE)--Following to the previous information on Oct. 28th. in 2024, we are excited to share our latest development status. We are pleased to announce that the data review committee (DMC) has approved the tolerability of the first three patients enrolled in the Phase I/II clinical trial of DFP-10917 in combination with Venetoclax (VEN) (NCT06382168) conducted at five US clinical sites for patients with acute myeloid leukemia (AML) who have failed/relapsed after standa...

Delta-Fly Pharma Inc.: Update for Development Status of DFP-17729

TOKUSHIMA, Japan--(BUSINESS WIRE)--We are excited to share our latest development status. We are pleased to announce that as a result of consultation with the PMDA on December 3rd, 2024, the Phase II/III clinical trial of DFP-17729 in combination with TS-1 versus TS-1 alone in patients with pancreatic cancer after third-line treatment was approved. In a Phase I/II study of DFP-17729 in combination with TS-1 in patients with end-stage pancreatic cancer, no significant difference was observed aga...
Back to Newsroom